21
Participants
Start Date
October 3, 2024
Primary Completion Date
October 27, 2028
Study Completion Date
October 27, 2028
BG-C477
Administered intravenously.
Chemotherapy
Administered in accordance with relevant local guidelines and/or prescribing information.
RECRUITING
Auckland City Hospital, Auckland
RECRUITING
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
NOT_YET_RECRUITING
Jiamusi Cancer Hospital, Jiamusi
NOT_YET_RECRUITING
Fudan University Shanghai Cancer Center, Shanghai
NOT_YET_RECRUITING
The First Affiliated Hospital of Soochow University, Suzhou
NOT_YET_RECRUITING
Jining No Peoples Hospital East Branch, Jining
NOT_YET_RECRUITING
Linyi Peoples Hospital Beicheng Branch, Linyi
NOT_YET_RECRUITING
The First Affiliated Hospital of Nanchang University Branch Xianghu, Nanchang
RECRUITING
Chongqing University Cancer Hospital, Chongqing
RECRUITING
Sun Yat Sen University Cancer Center, Guangzhou
NOT_YET_RECRUITING
The Sixth Affiliated Hospital, Sun Yat Sen University, Guangzhou
NOT_YET_RECRUITING
The Tumor Hospital Affiliated to Guangxi Medical Universitywuxiang Branch, Nanning
RECRUITING
City of Hope National Medical Center, Duarte
RECRUITING
Yale University, Yale Cancer Center, New Haven
RECRUITING
The University of Kansas Cancer Center, Westwood
NOT_YET_RECRUITING
John Theurer Cancer Center Hackensack University Medical Center, Hackensack
RECRUITING
The University of Texas Md Anderson Cancer Center, Houston
RECRUITING
Blacktown Cancer and Haematology Centre, Blacktown
RECRUITING
Cancer Research South Australia, Adelaide
RECRUITING
The Alfred Hospital, Melbourne
RECRUITING
One Clinical Research, Nedlands
Lead Sponsor
BeiGene
INDUSTRY